Cargando…
Updates on Prevention of Hemorrhagic and Lacunar Strokes
Intracerebral hemorrhage (ICH) and lacunar infarction (LI) are the major acute clinical manifestations of cerebral small vessel diseases (cSVDs). Hypertensive small vessel disease, cerebral amyloid angiopathy, and hereditary causes, such as Cerebral Autosomal Dominant Arteriopathy with Subcortical I...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Stroke Society
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007298/ https://www.ncbi.nlm.nih.gov/pubmed/29886717 http://dx.doi.org/10.5853/jos.2018.00787 |
_version_ | 1783333011426639872 |
---|---|
author | Tsai, Hsin-Hsi Kim, Jong S. Jouvent, Eric Gurol, M. Edip |
author_facet | Tsai, Hsin-Hsi Kim, Jong S. Jouvent, Eric Gurol, M. Edip |
author_sort | Tsai, Hsin-Hsi |
collection | PubMed |
description | Intracerebral hemorrhage (ICH) and lacunar infarction (LI) are the major acute clinical manifestations of cerebral small vessel diseases (cSVDs). Hypertensive small vessel disease, cerebral amyloid angiopathy, and hereditary causes, such as Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), constitute the three common cSVD categories. Diagnosing the underlying vascular pathology in these patients is important because the risk and types of recurrent strokes show significant differences. Recent advances in our understanding of the cSVD-related radiological markers have improved our ability to stratify ICH risk in individual patients, which helps guide antithrombotic decisions. There are general good-practice measures for stroke prevention in patients with cSVD, such as optimal blood pressure and glycemic control, while individualized measures tailored for particular patients are often needed. Antithrombotic combinations and anticoagulants should be avoided in cSVD treatment, as they increase the risk of potentially fatal ICH without necessarily lowering LI risk in these patients. Even when indicated for a concurrent pathology, such as nonvalvular atrial fibrillation, nonpharmacological approaches should be considered in the presence of cSVD. More data are emerging regarding the presentation, clinical course, and diagnostic markers of hereditary cSVD, allowing accurate diagnosis, and therefore, guiding management of symptomatic patients. When suspicion for asymptomatic hereditary cSVD exists, the pros and cons of prescribing genetic testing should be discussed in detail in the absence of any curative treatment. Recent data regarding diagnosis, risk stratification, and specific preventive approaches for both sporadic and hereditary cSVDs are discussed in this review article. |
format | Online Article Text |
id | pubmed-6007298 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Korean Stroke Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-60072982018-06-21 Updates on Prevention of Hemorrhagic and Lacunar Strokes Tsai, Hsin-Hsi Kim, Jong S. Jouvent, Eric Gurol, M. Edip J Stroke Special Review Intracerebral hemorrhage (ICH) and lacunar infarction (LI) are the major acute clinical manifestations of cerebral small vessel diseases (cSVDs). Hypertensive small vessel disease, cerebral amyloid angiopathy, and hereditary causes, such as Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), constitute the three common cSVD categories. Diagnosing the underlying vascular pathology in these patients is important because the risk and types of recurrent strokes show significant differences. Recent advances in our understanding of the cSVD-related radiological markers have improved our ability to stratify ICH risk in individual patients, which helps guide antithrombotic decisions. There are general good-practice measures for stroke prevention in patients with cSVD, such as optimal blood pressure and glycemic control, while individualized measures tailored for particular patients are often needed. Antithrombotic combinations and anticoagulants should be avoided in cSVD treatment, as they increase the risk of potentially fatal ICH without necessarily lowering LI risk in these patients. Even when indicated for a concurrent pathology, such as nonvalvular atrial fibrillation, nonpharmacological approaches should be considered in the presence of cSVD. More data are emerging regarding the presentation, clinical course, and diagnostic markers of hereditary cSVD, allowing accurate diagnosis, and therefore, guiding management of symptomatic patients. When suspicion for asymptomatic hereditary cSVD exists, the pros and cons of prescribing genetic testing should be discussed in detail in the absence of any curative treatment. Recent data regarding diagnosis, risk stratification, and specific preventive approaches for both sporadic and hereditary cSVDs are discussed in this review article. Korean Stroke Society 2018-05 2018-05-31 /pmc/articles/PMC6007298/ /pubmed/29886717 http://dx.doi.org/10.5853/jos.2018.00787 Text en Copyright © 2018 Korean Stroke Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Special Review Tsai, Hsin-Hsi Kim, Jong S. Jouvent, Eric Gurol, M. Edip Updates on Prevention of Hemorrhagic and Lacunar Strokes |
title | Updates on Prevention of Hemorrhagic and Lacunar Strokes |
title_full | Updates on Prevention of Hemorrhagic and Lacunar Strokes |
title_fullStr | Updates on Prevention of Hemorrhagic and Lacunar Strokes |
title_full_unstemmed | Updates on Prevention of Hemorrhagic and Lacunar Strokes |
title_short | Updates on Prevention of Hemorrhagic and Lacunar Strokes |
title_sort | updates on prevention of hemorrhagic and lacunar strokes |
topic | Special Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007298/ https://www.ncbi.nlm.nih.gov/pubmed/29886717 http://dx.doi.org/10.5853/jos.2018.00787 |
work_keys_str_mv | AT tsaihsinhsi updatesonpreventionofhemorrhagicandlacunarstrokes AT kimjongs updatesonpreventionofhemorrhagicandlacunarstrokes AT jouventeric updatesonpreventionofhemorrhagicandlacunarstrokes AT gurolmedip updatesonpreventionofhemorrhagicandlacunarstrokes |